Filing Details
- Accession Number:
- 0001209191-20-064531
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-12-18 19:18:23
- Reporting Period:
- 2020-12-17
- Accepted Time:
- 2020-12-18 19:18:23
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1001233 | Sangamo Therapeutics Inc | SGMO | Biological Products, (No Disgnostic Substances) (2836) | 680359556 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1547959 | Saira Ramasastry | C/O Sangamo Therapeautics, Inc. 7000 Marina Blvd Brisbane CA 94405 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2020-12-17 | 10,000 | $5.99 | 25,000 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2020-12-17 | 10,000 | $13.27 | 15,000 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right-to-Buy) | Disposition | 2020-12-17 | 10,000 | $0.00 | 10,000 | $5.99 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2026-06-13 | No | 4 | M | Direct |
Footnotes
- Includes 10,000 shares of common stock subject to restricted stock units ("RSUs") granted on May 15, 2020. The RSUs will fully vest on the earlier of (x) May 15, 2021 (the first anniversary of the date of grant) or (y) the day prior to Issuer's 2021 annual stockholders meeting, subject to the Reporting Person's Continuous Service through such dates as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended") and subject to acceleration as defined in the 2018 EIP, as amended.
- The price reported is a weighted average price. The shares were sold at prices ranging from $13.26 to $13.32 The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- The option was immediately exercisable for all option shares, but shares purchased under the option were subject to certain repurchase rights by the Issuer upon the cessation of the Reporting Person's service on the Board of Directors of the Issuer. The shares subject to each option vested in monthly installments upon completion of each month of Board service over a three year period measured from the date of grant.
Billionaire Hedge Funds
